{
    "clinical_study": {
        "@rank": "100668", 
        "acronym": "DEDICA", 
        "arm_group": [
            {
                "arm_group_label": "Standard dose heparin", 
                "arm_group_type": "Active Comparator", 
                "description": "Bolus of 100 UI/Kg of heparin. Activated clotting time (ACT) > 300 sec. during the procedure"
            }, 
            {
                "arm_group_label": "Low-dose heparin", 
                "arm_group_type": "Experimental", 
                "description": "Bolus of 50 UI/Kg heparin with a target ACT during the procedure of >200 sec."
            }
        ], 
        "brief_summary": {
            "textblock": "International guidelines support the use of a full-dose heparin  (anticoagulants) during\n      coronary intervention. However, a lower dose of heparin may be adequate, thanks to advances\n      in angioplasty techniques and the widespread use of pretreatment with two antiplatelet\n      agents.\n\n      Thus the investigators designed a study comparing safety and efficacy of standard dose\n      heparin (100 UI/Kg) versus low-dose (50 UI/Kg) in patients undergoing coronary angioplasty\n      who are on aspirin and clopidogrel at the time of the procedure."
        }, 
        "brief_title": "DEDICA (Dose of HEparin During Coronary Angioplasty) Trial", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Stable Angina", 
            "Angina, Unstable", 
            "Non-ST Elevation (NSTEMI) Myocardial Infarction"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Angina Pectoris", 
                "Angina, Unstable", 
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  Patients undergoing coronary angioplasty will be randomised to standard vs. low-dose\n           heparin. the study will include \"all-comers\" (patients with either stable angina or\n           acute coronary syndromes); only patients with ST-elevation myocardial infarction will\n           be excluded.\n\n        -  An ACT (activated clotting time) will be performed after the initial bolus of heparin:\n           for the standard dose group the target ACT will be > 300 sec. (as recommended by\n           guidelines) while for the low-dose the target ACT will be > 180 sec.\n\n      Aim of the study is to show equivalence in ischemic events between the two doses of heparin,\n      in order to confirm the safety of lower dose of heparin in contemporary coronary\n      interventions."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Stable angina, unstable angina or Non-ST elevation myocardial infarction undergoing\n             coronary angioplasty.\n\n          -  Mandatory pretreatment with aspirin and clopidogrel\n\n        Exclusion Criteria:\n\n          -  ST elevation myocardial infarction\n\n          -  Coronary interventions with rotational atherectomy\n\n          -  Coronary interventions on chronic total occlusions (CTO)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01694459", 
            "org_study_id": "596-2012-D"
        }, 
        "intervention": [
            {
                "arm_group_label": "Low-dose heparin", 
                "description": "Bolus of 50 UI/Kg of heparin at the beginning of coronary interventions", 
                "intervention_name": "Low-dose heparin", 
                "intervention_type": "Drug", 
                "other_name": "50 UI/Kg bolus heparin"
            }, 
            {
                "arm_group_label": "Standard dose heparin", 
                "description": "Bolus of 100 UI/Kg of heparin at the beginning of coronary interventional procedure.", 
                "intervention_name": "Standard dose heparin", 
                "intervention_type": "Drug", 
                "other_name": "100 Ui/Kg bolus heparin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Calcium heparin", 
                "Heparin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "angioplasty", 
            "heparin", 
            "trial"
        ], 
        "lastchanged_date": "September 26, 2012", 
        "location": {
            "contact": {
                "last_name": "Francesco Pelliccia, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Rome", 
                    "country": "Italy", 
                    "zip": "00161"
                }, 
                "name": "University of Rome La Sapienza"
            }, 
            "investigator": {
                "last_name": "Carlo Gaudio, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison of Low-dose Heparin Versus Standard Dose Heparin During Coronary Interventions (DEDICA Trial)", 
        "other_outcome": {
            "description": "Major bleeding according to STEEPLE criteria", 
            "measure": "Major bleeding", 
            "safety_issue": "Yes", 
            "time_frame": "30 days"
        }, 
        "overall_contact": {
            "email": "vpasceri@hotmail.com", 
            "last_name": "Vincenzo Pasceri, MD", 
            "phone": "+39063306", 
            "phone_ext": "2504"
        }, 
        "overall_contact_backup": {
            "email": "md4151@mclink.it", 
            "last_name": "Francesco Pelliccia, MD", 
            "phone": "+393483392006"
        }, 
        "overall_official": [
            {
                "affiliation": "San Filippo Neri Hospital", 
                "last_name": "Vincenzo Pasceri, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University of Roma La Sapienza", 
                "last_name": "Francesco Pelliccia, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "MACE (death, myocardial infarction, target vessel revascularization) + stent thrombosis + major bleeding (TIMI definition)", 
            "measure": "MACE  + stent thrombosis + major bleeding (TIMI definition)", 
            "safety_issue": "Yes", 
            "time_frame": "30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01694459"
        }, 
        "responsible_party": {
            "investigator_affiliation": "San Filippo Neri General Hospital", 
            "investigator_full_name": "Vincenzo Pasceri", 
            "investigator_title": "Attending Cardiologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "MACE = death, myocardial infarction, target vessel revascularization", 
                "measure": "MACE", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Major bleeding according to TIMI criteria", 
                "measure": "Major Bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Stent thrombosis (definite or probable according to ARC criteria)", 
                "measure": "Stent thrombosis", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Any CK MB increase >3 times upper limit of normal or >50% baseline levels (if baseline levels already >then upper limit of normal)", 
                "measure": "CK-MB increase", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }
        ], 
        "source": "San Filippo Neri General Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Roma La Sapienza", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "San Filippo Neri General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}